Roseburia

Your colon lining does something unusual. It doesn't run mainly on the sugar in your blood. It runs on butyrate, a short fatty acid made by bacteria fermenting fiber a few millimeters away. Roseburia is one of the main groups doing that fermenting.

That's why this number keeps showing up in studies of ulcerative colitis, colorectal cancer, rheumatoid arthritis, and stroke severity. What it can't yet do is tell you where your own number should sit. There are no validated reference ranges for this organism, and a single reading in isolation diagnoses nothing.

What This Test Actually Measures

Roseburia is a genus of oxygen-intolerant, Gram-positive organisms living in your colon, part of the Lachnospiraceae family. The species named most often in research are R. intestinalis, R. hominis, R. faecis, and R. inulinivorans, with R. cecicola also described.

The lab method copies and counts specific stretches of bacterial DNA in your stool sample. It is not measuring butyrate itself. It is counting organisms known to make it, which is a reasonable proxy but not the same thing. If you want the metabolic output directly, that requires a separate short-chain fatty acid measurement.

Much of the evidence below comes from studies of one species, such as R. hominis or R. intestinalis. A genus-level stool result can move in the same direction, but it is not the same measurement.

One more limit matters. Stool captures bacteria shed into the stool stream, not the ones living against your intestinal wall. Studies that sampled intestinal tissue directly, rather than stool, have found Roseburia differences that stool testing can miss. So a normal-looking stool result does not rule out changes at the intestinal wall surface.

Why Butyrate Matters So Much

Roseburia species ferment complex carbohydrates and resistant starch into short-chain fatty acids, with butyrate as the main product. Butyrate is the principal energy source for the cells lining your colon. Starve those cells and the barrier they form gets leakier.

Butyrate does more than feed. It pushes your immune system to make regulatory T cells. Those cells help calm inflammation. It also strengthens the protein seals between neighboring gut cells. That combination is why low Roseburia keeps turning up next to inflammation markers in unrelated diseases.

This mechanism is well characterized. What follows from it in your own body is much less certain, and the sections below keep that distinction visible.

Ulcerative Colitis and Crohn's Disease

The strongest human evidence sits here. In a study of 214 people, 127 with ulcerative colitis and 87 healthy controls, those with colitis had markedly less R. hominis, and the depletion tracked with how severe their disease was. Lower counts, worse disease. In that same study short-chain fatty acids were also reduced in colitis but did not correlate directly with the bacterial counts, a reminder that counting the producers is not the same as measuring what they produce.

Roseburia also carries some forward-looking signal in inflammatory bowel disease. In 21 people who had their colon removed and an internal pouch constructed, a five-organism stool signature measured before surgery predicted pouchitis afterward. Reduced Roseburia was one component of that signature rather than a standalone predictor, and the group was small. In a separate group followed for ten years, tracking R. hominis alongside other microbial features helped predict who would eventually need their therapy escalated, though that comes from one cohort and the accuracy has not been reproduced elsewhere.

One observational cohort found that Roseburia depletion appeared before fecal calprotectin, the standard inflammation marker, started rising ahead of a Crohn's flare. That is an interesting lead, not a validated early-warning test. Nobody has run the trial showing that acting on that signal changes what happens next.

Colorectal Cancer

People with colorectal cancer have less fecal Roseburia and fewer bacterial genes for making butyrate. One study comparing 444 people with colorectal cancer against 575 controls found R. intestinalis depleted in stool. Microbiome models can separate cancer from healthy controls in the cohorts that built them, but no Roseburia cutoff has been established, and this is not a screening test.

The more interesting finding is about treatment. Human stool data link R. intestinalis with checkpoint-therapy response. The treatment-boosting experiment was in mice, where R. intestinalis or butyrate made resistant tumors respond better to anti-PD-1 therapy by activating tumor-killing T cells.

Be careful with what this does and doesn't mean for screening. Fecal immunochemical testing and colonoscopy detect bleeding and visible lesions. Roseburia depletion reflects the state of the fiber-fermenting community. Neither substitutes for the other, and only one of them is guideline-backed for cancer screening. Keep your colonoscopy schedule.

Heart, Metabolic, and Kidney Findings

In a study of 135 people with acute ischemic stroke, those with more Roseburia had milder neurological deficits and better recovery. A separate cohort of stroke patients found that low Roseburia on admission independently predicted stroke-associated pneumonia, roughly halving the odds in people who had more of it.

Depletion also shows up in type 2 diabetes, in chronic kidney disease where it correlates inversely with C-reactive protein and cystatin C, and in non-alcoholic fatty liver disease. Higher abundance has also been linked with leaner body composition, normal blood pressure, and lower triglycerides and LDL in observational work.

Every one of these is a snapshot taken after the disease already existed. In the stroke study, the authors named the problem directly: they had no samples from before the stroke, so they can't say whether low Roseburia contributed to worse strokes or whether worse strokes drove Roseburia down.

Autoimmune and Other Associations

A small PCR-based study found lower R. faecis in rheumatoid arthritis, and independent cohorts using other methods have found Roseburia depleted in rheumatoid arthritis too, so the direction is reasonably consistent even where the species-level detail rests on one small study. Tissue sampling in inflammatory bowel disease-associated arthritis found depleted R. intestinalis, but only in women. People with anorexia nervosa show reduced Roseburia diversity that doesn't fully recover with partial weight restoration.

One genetic study used inherited variation as a natural experiment and suggested a protective effect of gut Roseburia against gum disease, working partly through immune cell signaling. That is a causal hint, but not a trial showing that raising Roseburia prevents gum disease.

Why the Same Finding Points Both Ways

Reading the list above, you'd conclude more is always better. Two findings complicate that. Pregnant women with overweight or obesity who had fasting ketones in their urine had higher Roseburia, not lower. And one small cohort with diabetic cognitive impairment found elevated levels alongside a disordered short-chain fatty acid profile. That second one is an outlier: across the broader diabetes literature, Roseburia and butyrate more often run low.

There is no contradiction once you stop treating this as a good-number bad-number marker. It's a readout of fermentation activity. Usually high fermentation of fiber means a well-fed gut lining, which is protective. But fermentation responds to whatever substrate is available and to the metabolic state of the host, so the same elevated count can mean different things in a person in ketosis than in a person eating a high-fiber diet. Context sets the meaning, not the number.

Why a Single Reading Can Fool You

This is why one result can mislead. Dense daily sampling over six weeks found that more than three-quarters of gut genera vary more within one person over time than between different people, with absolute abundances swinging up to a hundredfold in about 40% of the abundant ones. Stool moisture was the largest single driver, diet second. Over a full year, about a quarter of all compositional variance was within-person rather than between-person.

Several things can distort one reading without any change in your gut health:

• Stool consistency and transit time: looser or faster-moving stool dilutes and shifts measured abundances. This was the dominant source of day-to-day variation in careful daily sampling.
• Recent antibiotics: amoxicillin-clavulanate drops Roseburia during a seven-day course. How quickly it comes back is unsettled. One randomized study found the community still unlike its starting state two weeks after the course ended; another found healthy adults back at pre-treatment composition roughly a week after stopping. Either way, a result taken in that window tells you more about the antibiotic than about you.
• What you ate in the preceding days: fermentable carbohydrate intake moves this number quickly. A week of travel eating and a week of lentils and oats will not give you the same answer.
• The lab method itself: DNA extraction technique, primer choice, and whether the lab used targeted PCR versus broad sequencing all change the number for the same sample. Cross-lab comparisons are not reliable.

Host factors that have nothing to do with disease, including age, body weight, sex, and medications, confound microbiome comparisons broadly enough that carefully matched analyses often shrink or erase differences that looked convincing in unmatched ones.

Tracking Your Trend

Given that variability, one measurement is a data point, not an answer. The value of this test comes mostly from repetition under consistent conditions.

Get a baseline. If you're making a deliberate change, such as substantially raising fiber intake or shifting toward less-refined carbohydrates, retest in three to six months, sampling under similar conditions: same lab, similar diet in the days beforehand, well away from any antibiotic course. Then at least annually if you're managing an ongoing gut or inflammatory condition. Longer-term work sampling every six months for two years found overall microbiome structure reasonably reproducible at the genus level, so annual tracking is not unreasonable, but individual genera move more than the whole community does.

What you're looking for is direction and persistence. A single low reading means little. A low reading that stays low across three samples taken months apart, under comparable conditions, is a stronger signal about your fermentation capacity.

What to Do With an Unexpected Result

If Roseburia comes back low and you have gut symptoms, the useful next step is pairing it with markers that measure something different. Fecal calprotectin tells you whether inflammatory white blood cells are attacking your intestinal lining. Fecal short-chain fatty acids tell you whether the butyrate output is actually reduced, not just the bacteria counted as making it. A low Roseburia count alongside a raised calprotectin is a very different picture from low Roseburia with normal calprotectin, and the pair is worth more than either alone.

Look at the rest of the panel too. Roseburia depletion alongside an expansion of inflammation-linked organisms suggests a broader shift in the community. Roseburia low with everything else unremarkable more often reflects diet, a recent antibiotic course, or the sampling variability described above. Retest before concluding anything.

If symptoms are present, particularly blood in stool, persistent diarrhea, unexplained weight loss, or nighttime symptoms, that's a gastroenterologist conversation, and it should not wait on a microbiome result. Endoscopy and calprotectin, not bacterial profiling, are what diagnose inflammatory bowel disease. If you're due for colorectal cancer screening, get the guideline-recommended test regardless of what this number says.

An isolated low result in someone with no symptoms and no risk factors is not a reason to do anything dramatic. It's a reason to look at your fiber intake, retest in a few months, and see whether the direction holds.

How Mature This Marker Is

This is a research-grade measurement being sold clinically. It has no standardized cutpoints, no consensus reference range, and no trial showing that measuring it and acting on it improves any hard outcome. In a large metagenomic analysis of people with a family history of colorectal cancer, Roseburia differences were present but failed to reach statistical significance or change management. In exploratory cohorts for conditions like rosacea, nominal Roseburia differences disappeared once the analysis corrected for the number of comparisons being made.

That doesn't make it worthless. It makes it a marker to track rather than a marker to diagnose from. Getting a baseline now and watching your own trajectory gives you personal data to compare against as the science firms up. Just don't let the number override a symptom or a screening schedule.